Springboard’s Healthcare & Technology Innovation Program is for women-led healthcare companies seeking growth, funding, and connections to experts and strategic partners for product development and expansion.
The Healthcare & Technology Innovation Program includes, but is not limited to, innovation in awareness and education, diagnosis, treatment, ongoing care and wellness related to: medical devices, wearables, diagnostics, therapeutics, biotechnology, pharmaceuticals, longevity, drug discovery and development, artificial intelligence, machine learning, application software, and platform technologies.
Now Open!
July 15, 2024
August 2024
September 9-20, 2024
Q4 2024
Aloe Therapeutics’ mission is to improve outcomes for patients with hard to treat solid tumors and limited therapeutic options. Our lead platform, Allo Immunotherapy (AIM), is a nontraditional cell-based therapy implanted at the tumor site. AIM acts as “bait” to activate the immune system and increase response rates to commonly used cancer therapies.
Concerto Biosciences examines the microbial world with unmatched experimental depth to discover breakthrough microbe-based products. In partnership with a diverse array of biotech and biopharma companies, Concerto aims to unleash a new era of microbial research and microbe-based products.
Panakeia’s Gen AI-driven software provides comprehensive (5+ different types such as genetic, protein, RNA changes) multi-omic information directly from routinely used images of tissues & cells in minutes instead of days or weeks, eliminating the need for wet-lab assays.
Panakeia’s platform determines the changes of over 4,500 known molecular cancer markers across 30+ solid cancers with two UKCA & CE-marked breast & colon cancer products deployed in the clinic.
PHIOGEN is a late-stage pre-clinical stage company developing live biotherapeutic products for drug resistant and recurrent bacterial infections, located at the Texas Medical Center in Houston.
Revealix offers a mobile smart foot health platform that uses advanced imaging and risk screening technology to digitize diabetic foot screenings, ensuring preventive care is accessible in any location, especially underserved communities.
RT MicroDx is pioneering the next generation of at-home diagnostic testing with our Triple-A solution—Affordable, Accurate, and At-Home. Our innovative technology offers a simple, over-the-counter molecular diagnostic test that provides PCR-quality results at a fraction of the cost and time. This solution not only meets the growing demand for at-home healthcare but also ensures accuracy and affordability, bridging a critical gap in global diagnostic access.
RubyWell helps unpaid family caregivers maintain financial stability by providing access to training and payment for the care they provide to aging loved ones.
If you are interested in sponsoring, applying, or learning more about the program, please email [email protected].
